Congleton Jon 4
4 · Mineralys Therapeutics, Inc. · Filed Jan 13, 2026
Insider Transaction Report
Form 4
Congleton Jon
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
[F1][F2]2026-01-12$32.21/sh−9,119$293,707→ 646,268 total - Sale
Common Stock
[F1][F3]2026-01-12$33.15/sh−7,117$235,932→ 639,151 total
Footnotes (3)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on January 28, 2025.
- [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.8400 to $32.8028. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
- [F3]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.8439 to $33.5000. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
Signature
/s/ Adam Levy, Attorney-in-fact|2026-01-13